Just One Question Podcast: S3 E6 – Biotech expert Seth and Nick discuss revolutionary regenerative medicine treatments

Seth Ettenberg and Nick discuss how technology is used to develop regenerative medicine for conditions such as Parkinson’s disease and Alzheimer’s disease.

Seth Ettenberg is CEO and President of BlueRock Therapeutics, a wholly owned subsidiary of Bayer. He’s a biotech entrepreneur, on the cutting edge of something called regenerative medicine.

Click Here To Listen

Related News

Press Releases

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

December 17, 2025
Press Releases

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025
Press Releases

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

December 17, 2025
Press Releases

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025
See All